comparemela.com

Latest Breaking News On - Nobuaki matsubara - Page 1 : comparemela.com

ESMO 2023: Talazoparib plus Enzalutamide in Metastatic Castration Resistant Prostate Cancer: Subgroup Analyses of the All-Comers Cohort from TALAPRO-2 by HRR Status

ESMO 2023: Talazoparib plus Enzalutamide in Metastatic Castration Resistant Prostate Cancer: Subgroup Analyses of the All-Comers Cohort from TALAPRO-2 by HRR Status
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

PROfound: Phase 3 Study of Olaparib vs Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations

PROfound: Phase 3 Study of Olaparib vs Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

ASCO GU 2023: Pembrolizumab plus Docetaxel for Patients with mCRPC: Randomized, Double-Blind, Phase 3 KEYNOTE-921 Study

ASCO GU 2023: Pembrolizumab plus Docetaxel for Patients with mCRPC: Randomized, Double-Blind, Phase 3 KEYNOTE-921 Study
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

ASCO GU 2022: Long-Term Safety of Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2022: Long-Term Safety of Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

New class of drug leads to 30% reduced risk of death for bladder cancer patients

 E-Mail A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust. The results are published in the New England Journal of Medicine and were presented at the 2021 American Society of Clinical Oncology s Genitourinary Cancers Symposium. Urothelial cancer is the most common type of bladder cancer (90 percent of cases) and can also be found in the renal pelvis (where urine collects inside the kidney), ureter (tube that connects the kidneys to the bladder) and urethra. Globally, approximately 549,000 new cases of bladder cancer and 200,000 deaths are reported annually.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.